Manesh Patel

All right, here's Peter.

So a few weeks ago, I spoke with our listener, Manesh Patel.

And before I jump into his story, I should warn you, I have been watching a lot of horror movies lately.

And talking to Manesh, I couldn't help but feel like his experience was like a series of horror films tied together.

So Nobel Laureate session, like, seriously, h- how can you possibly miss that? Presidential session, it's always amazing.

There are always big announcements about cardiology, the specialty, but there's alw- always a compelling presidential lecture, and, and this year it's Phyllis Lee to Manesh Patel.

So those would be the, the, the two of the not, not to misses.

So one area of science that's underappreciated but deserves more attention.

So there genuinely is something for everyone, for every clinician, for every scientist, and for every practitioner in cardiac care.

So this is fantastic, and I can't wait to see you in Chicago.

Well, uh, and everyone, all of you listeners, don't miss out the AHA 2026 Scientific Sessions in the great city of Chicago with Dr. Joe Chike-KW leading the way and Manesh Patel as the president of the AHA.

November 6th, 7th, 8th, 9th, 10th, not too late to register.

Yeah.

Uh, Manesh Patel.

I'm the, uh, head of Data Centre Development at Radian, and, uh, we are a, a new entrant to the market this year.

Uh, owned by the Brookfield AI Infrastructure Fund and, uh, focused on delivering compute at a global level.

and was also associated with a lower risk of a composite of death from any cause or hospitalization for heart failure through three years.

Manesh Patel from Duke University School of Medicine, Durham, North Carolina, writes in an editorial that, as with other trials of transcatheter valve therapies, the trial by Hausleiter and co-authors moves forward both the field of transcatheter tricuspid valve therapies, and the care of patients with severe tricuspid regurgitation.

The trial identified the patients who are most likely to benefit from the tricuspid repair procedure, and the findings of improved survival and freedom from hospitalization for heart failure provide us with clear differences in meaningful clinical outcomes that translate to patient-related benefits in this high-risk patient population.

However, there is still room for improvement, and as with other transcatheter therapies, transcatheter tricuspid valve repair is neither the first nor the last innovation through which rigorous testing and population refinement provide a roadmap for implementation of improved systems of care for our patients with severe tricuspid regurgitation.

And it is not just opportunistic plaintiffs.

Three Columbia legal scholars, Amelia Miazad, Barack Orbash, and Manesh Patel, wrote that the labs basically cannot legally agree to slow down the way people imagine.

Do you have their exact wording? Because legal scholars tend to be careful, and I want to hear how strongly they actually put it before I believe it is that clear cut.

Their line is, quote, a bare agreement among competitors to slow innovation does not become lawful merely because its stated purpose is to reduce risks.